Table 2

Demographic information of patients with COPD providing serums

DataControl subjects
(n=16)
Patients with COPD
(n=29)
Patients with COPD-PH
(n=36)
P value
Age (year)70.06±8.0666.45±10.1772.10±8.8340.0751
Sex (male)7 (43.8%)25 (86.2%)32 (88.9%)0.001
Smoking (pack-year)N/A30.0 (IQR: 5.5–49.5)37.5 (IQR: 12.5–58.0)0.3843
sPAPN/AN/A56.59±2.40N/A
FEV1/FVC (%)N/A47.09 (IQR: 39.07–62.34)41.77 (IQR: 35.13–57.95)0.3992
FVC/predicted value (%)N/A63.40±21.8465.39±22.970.8028
BNP (pg/mL)N/A55.33 (IQR: 29.08–165.4)61.70 (IQR: 35.00–400.8)0.2848
CRP (mg/dL)N/A0.65 (IQR: 0.40–8.60)1.01 (IQR: 0.615–2.315)0.9113
History
Hypertension014 (48.3%)14 (38.9%)0.463
Cardiovascular diseases06 (20.7%)4 (11.1%)0.321
Diabetes05 (17.2%)6 (16.7)1.000
Tumours01 (3.4%)2 (5.5%)1.000
Tuberculosis (past)02 (6.9%)3 (8.3%)1.000
  • BNP, B-type natriuretic peptide; CRP, C reactive protein; N/A, not available; PH, pulmonary hypertension; sPAP, systolic pulmonary artery pressure .